Table 2.
Demographics, serologic types and clinical weakness in patients included in the analyses (n = 43)
| Demographics and MSA types |
CMAS Mean (range) |
MMT8 Mean (range) |
CK (U/L) Mean (range) |
|
|---|---|---|---|---|
| Age at diagnosis, years | 6 (2–16) | |||
| Sex | n (%) | |||
| Male | 11 (25.6) | |||
| Female | 32 (74.4) | |||
| Race | n (%) | |||
| Hispanic | 18 (41.9) | |||
| White | 17 (39.5) | |||
| Black | 6 (14.0) | |||
| Other | 2 (4.6) | |||
| MSA | n (%) | |||
| Anti-NXP-2 | 9 (20.9) | 21 (0–51) | 59 (32–80) | 1019 (47–4681) |
| Anti-Mi-2 | 5 (11.6) | 15 (0–46) | 25 (21–30) | 10,366 (1491-18,992) |
| Anti-MDA-5 | 3 (7.0) | 49 (46–52) | 72 (64–80) | 37 (13–50) |
| Anti-Tif-1γ | 1 (2.3) | 32 | 59 | 402 |
| Anti-SRP | 1 (2.3) | 48 | 76 | 132 |
| Anti-PL-7 | 1 (2.3) | 2 | 45 | 13,972 |
| Multiple MSAs | 6 (14.0) | 40 (32–48) | 30 (21–39) | 1022 (93–3860) |
| No MSA | 17 (39.5) | 27 (4–46) | 55 (36–76) | 2548 (26–12,809) |